Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
tau Proteins | 22 | 2019 | 208 | 4.080 |
Why?
|
Neurodegenerative Diseases | 11 | 2016 | 251 | 1.890 |
Why?
|
Drosophila Proteins | 12 | 2016 | 723 | 1.870 |
Why?
|
Primary Health Care | 5 | 2023 | 772 | 1.860 |
Why?
|
Drosophila melanogaster | 12 | 2016 | 771 | 1.830 |
Why?
|
Parkinson Disease | 8 | 2017 | 693 | 1.340 |
Why?
|
Tauopathies | 6 | 2014 | 62 | 1.270 |
Why?
|
Physician Assistants | 3 | 2020 | 66 | 1.250 |
Why?
|
alpha-Synuclein | 7 | 2018 | 123 | 1.230 |
Why?
|
Drosophila | 13 | 2017 | 781 | 1.170 |
Why?
|
Disease Models, Animal | 16 | 2016 | 4353 | 0.960 |
Why?
|
Alzheimer Disease | 12 | 2019 | 787 | 0.930 |
Why?
|
Eye | 7 | 2016 | 227 | 0.860 |
Why?
|
Genes, Modifier | 2 | 2012 | 11 | 0.790 |
Why?
|
Evidence-Based Practice | 2 | 2020 | 114 | 0.780 |
Why?
|
Continuity of Patient Care | 1 | 2023 | 154 | 0.730 |
Why?
|
Essential Tremor | 2 | 2022 | 89 | 0.690 |
Why?
|
Amyotrophic Lateral Sclerosis | 3 | 2013 | 146 | 0.670 |
Why?
|
Delivery of Health Care | 3 | 2020 | 606 | 0.660 |
Why?
|
Gene Regulatory Networks | 2 | 2012 | 354 | 0.650 |
Why?
|
Nerve Degeneration | 5 | 2009 | 126 | 0.640 |
Why?
|
Peptides | 5 | 2011 | 793 | 0.620 |
Why?
|
Glycogen Synthase Kinase 3 | 5 | 2011 | 64 | 0.610 |
Why?
|
Nurse Practitioners | 1 | 2019 | 44 | 0.610 |
Why?
|
Animals, Genetically Modified | 11 | 2016 | 315 | 0.600 |
Why?
|
Physicians, Primary Care | 1 | 2019 | 94 | 0.590 |
Why?
|
Aging | 4 | 2016 | 1184 | 0.590 |
Why?
|
Handwriting | 1 | 2017 | 8 | 0.570 |
Why?
|
Resistance Training | 1 | 2017 | 32 | 0.550 |
Why?
|
Quality of Health Care | 4 | 2023 | 389 | 0.550 |
Why?
|
Home Care Services | 1 | 2017 | 68 | 0.540 |
Why?
|
Preventive Health Services | 1 | 2017 | 58 | 0.530 |
Why?
|
Disease Management | 2 | 2019 | 519 | 0.520 |
Why?
|
United States Department of Veterans Affairs | 7 | 2019 | 668 | 0.520 |
Why?
|
Genetic Testing | 3 | 2012 | 1004 | 0.500 |
Why?
|
Patients | 1 | 2016 | 121 | 0.500 |
Why?
|
Animals | 38 | 2019 | 34146 | 0.480 |
Why?
|
Electronic Health Records | 1 | 2022 | 722 | 0.480 |
Why?
|
Neurofibrillary Tangles | 4 | 2014 | 26 | 0.460 |
Why?
|
Spinocerebellar Ataxias | 1 | 2017 | 255 | 0.450 |
Why?
|
Pigmentation | 2 | 2012 | 35 | 0.450 |
Why?
|
Chorea | 1 | 2014 | 39 | 0.450 |
Why?
|
Genomics | 2 | 2012 | 1486 | 0.440 |
Why?
|
Gait | 1 | 2015 | 146 | 0.440 |
Why?
|
Protein Processing, Post-Translational | 2 | 2013 | 355 | 0.440 |
Why?
|
DNA-Binding Proteins | 4 | 2017 | 2055 | 0.430 |
Why?
|
Autophagy | 2 | 2014 | 395 | 0.430 |
Why?
|
Early Detection of Cancer | 1 | 2017 | 356 | 0.430 |
Why?
|
Humans | 61 | 2023 | 124335 | 0.430 |
Why?
|
Antihypertensive Agents | 1 | 2016 | 397 | 0.420 |
Why?
|
RNA-Binding Proteins | 1 | 2017 | 577 | 0.410 |
Why?
|
Neuroglia | 1 | 2014 | 202 | 0.410 |
Why?
|
Memory Disorders | 1 | 2014 | 238 | 0.400 |
Why?
|
Research Design | 1 | 2016 | 687 | 0.400 |
Why?
|
Diabetic Ketoacidosis | 1 | 2014 | 160 | 0.390 |
Why?
|
Retinal Photoreceptor Cell Inner Segment | 1 | 2011 | 4 | 0.390 |
Why?
|
Memory | 2 | 2014 | 363 | 0.390 |
Why?
|
Amyloid beta-Peptides | 5 | 2019 | 210 | 0.380 |
Why?
|
Huntington Disease | 3 | 2010 | 143 | 0.380 |
Why?
|
Phosphorylation | 9 | 2014 | 1625 | 0.370 |
Why?
|
Diabetes Mellitus | 1 | 2019 | 853 | 0.360 |
Why?
|
Patient Care Team | 3 | 2022 | 546 | 0.360 |
Why?
|
Visual Fields | 1 | 2011 | 133 | 0.360 |
Why?
|
Immunotherapy | 3 | 2011 | 662 | 0.350 |
Why?
|
Aminopeptidases | 2 | 2006 | 19 | 0.340 |
Why?
|
Protein Multimerization | 5 | 2013 | 128 | 0.340 |
Why?
|
Vision Disorders | 1 | 2011 | 211 | 0.330 |
Why?
|
Movement Disorders | 2 | 2009 | 222 | 0.330 |
Why?
|
Mutation | 9 | 2014 | 5806 | 0.330 |
Why?
|
Neurons | 5 | 2016 | 1969 | 0.320 |
Why?
|
Diabetic Retinopathy | 1 | 2011 | 156 | 0.320 |
Why?
|
Cyclin-Dependent Kinase 5 | 1 | 2008 | 11 | 0.310 |
Why?
|
Specialization | 1 | 2009 | 75 | 0.310 |
Why?
|
Dopamine | 2 | 2009 | 284 | 0.310 |
Why?
|
Aged | 15 | 2023 | 19461 | 0.310 |
Why?
|
Models, Genetic | 2 | 2016 | 759 | 0.300 |
Why?
|
Medicine | 1 | 2009 | 97 | 0.300 |
Why?
|
Ubiquitin-Protein Ligases | 2 | 2009 | 356 | 0.290 |
Why?
|
Hypertension | 1 | 2016 | 1282 | 0.290 |
Why?
|
Neurology | 1 | 2009 | 108 | 0.290 |
Why?
|
Genes, Dominant | 1 | 2008 | 247 | 0.290 |
Why?
|
Lung Neoplasms | 1 | 2017 | 1604 | 0.280 |
Why?
|
Amyloidosis | 3 | 2011 | 67 | 0.260 |
Why?
|
Skin Diseases | 3 | 2011 | 124 | 0.250 |
Why?
|
Frontal Lobe | 3 | 2015 | 111 | 0.250 |
Why?
|
Middle Aged | 13 | 2019 | 26443 | 0.250 |
Why?
|
Brain | 6 | 2014 | 3004 | 0.240 |
Why?
|
Lewy Body Disease | 2 | 2015 | 18 | 0.230 |
Why?
|
Colorectal Neoplasms | 3 | 2016 | 566 | 0.230 |
Why?
|
Male | 20 | 2020 | 60990 | 0.230 |
Why?
|
Pastoral Care | 2 | 2014 | 3 | 0.230 |
Why?
|
Biomedical Research | 1 | 2009 | 518 | 0.220 |
Why?
|
United States | 9 | 2023 | 10766 | 0.210 |
Why?
|
Female | 19 | 2020 | 66271 | 0.210 |
Why?
|
Quality Improvement | 3 | 2023 | 639 | 0.210 |
Why?
|
Inappropriate Prescribing | 1 | 2023 | 41 | 0.210 |
Why?
|
Glycerol | 2 | 2013 | 92 | 0.200 |
Why?
|
Glycogen Synthase Kinase 3 beta | 3 | 2011 | 58 | 0.200 |
Why?
|
Amyloid | 3 | 2011 | 65 | 0.200 |
Why?
|
Cell Death | 3 | 2016 | 240 | 0.200 |
Why?
|
Insect Proteins | 1 | 2002 | 99 | 0.190 |
Why?
|
Photoreceptor Cells, Invertebrate | 1 | 2002 | 60 | 0.190 |
Why?
|
Hospitals, Veterans | 2 | 2014 | 355 | 0.190 |
Why?
|
Eye Abnormalities | 1 | 2002 | 106 | 0.190 |
Why?
|
Trans-Activators | 2 | 2002 | 808 | 0.180 |
Why?
|
Mental Health Services | 2 | 2014 | 255 | 0.180 |
Why?
|
Mutation, Missense | 3 | 2013 | 868 | 0.180 |
Why?
|
Ambulatory Care Facilities | 1 | 2023 | 228 | 0.180 |
Why?
|
Nervous System Malformations | 1 | 2002 | 130 | 0.180 |
Why?
|
Membrane Proteins | 1 | 2008 | 1530 | 0.180 |
Why?
|
Iron Chelating Agents | 1 | 2019 | 14 | 0.170 |
Why?
|
Cellular Senescence | 1 | 2019 | 161 | 0.150 |
Why?
|
Phenotype | 4 | 2016 | 4257 | 0.150 |
Why?
|
Antibodies | 4 | 2015 | 372 | 0.150 |
Why?
|
Protein Binding | 2 | 2014 | 1748 | 0.140 |
Why?
|
Hand Strength | 1 | 2017 | 41 | 0.140 |
Why?
|
Organizational Innovation | 1 | 2017 | 44 | 0.140 |
Why?
|
Iron | 1 | 2019 | 267 | 0.140 |
Why?
|
Eligibility Determination | 1 | 2017 | 37 | 0.140 |
Why?
|
Health Personnel | 1 | 2022 | 505 | 0.140 |
Why?
|
Motor Skills | 1 | 2017 | 83 | 0.140 |
Why?
|
Glycerol Kinase | 2 | 2013 | 19 | 0.140 |
Why?
|
Reactive Oxygen Species | 1 | 2019 | 492 | 0.130 |
Why?
|
Medication Therapy Management | 1 | 2016 | 25 | 0.130 |
Why?
|
Incidental Findings | 1 | 2017 | 124 | 0.130 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 1 | 2016 | 51 | 0.130 |
Why?
|
Immunohistochemistry | 5 | 2015 | 1686 | 0.130 |
Why?
|
Proteins | 3 | 2006 | 1043 | 0.130 |
Why?
|
Age Factors | 2 | 2016 | 2805 | 0.130 |
Why?
|
Life Style | 1 | 2018 | 410 | 0.130 |
Why?
|
Cholesterol, LDL | 1 | 2019 | 560 | 0.120 |
Why?
|
Pharmacy Service, Hospital | 1 | 2016 | 49 | 0.120 |
Why?
|
Veterans Health | 1 | 2017 | 174 | 0.120 |
Why?
|
Patient Reported Outcome Measures | 1 | 2017 | 171 | 0.120 |
Why?
|
Enzyme Activation | 3 | 2011 | 623 | 0.120 |
Why?
|
Program Evaluation | 1 | 2017 | 449 | 0.120 |
Why?
|
Cerebral Amyloid Angiopathy | 1 | 2014 | 13 | 0.120 |
Why?
|
Exercise Test | 1 | 2015 | 248 | 0.120 |
Why?
|
RNA Interference | 2 | 2013 | 503 | 0.120 |
Why?
|
Supranuclear Palsy, Progressive | 1 | 2014 | 29 | 0.110 |
Why?
|
Cell Line, Tumor | 4 | 2014 | 3342 | 0.110 |
Why?
|
Retina | 2 | 2016 | 454 | 0.110 |
Why?
|
Transgenes | 2 | 2008 | 338 | 0.110 |
Why?
|
Feasibility Studies | 1 | 2017 | 762 | 0.110 |
Why?
|
Peptide Fragments | 2 | 2016 | 749 | 0.110 |
Why?
|
Comprehensive Health Care | 1 | 2014 | 18 | 0.110 |
Why?
|
Behavior Therapy | 1 | 2016 | 257 | 0.110 |
Why?
|
Imaginal Discs | 1 | 2013 | 11 | 0.110 |
Why?
|
Medication Errors | 1 | 2016 | 184 | 0.110 |
Why?
|
Surveys and Questionnaires | 2 | 2022 | 3731 | 0.110 |
Why?
|
Immunization, Passive | 1 | 2014 | 120 | 0.110 |
Why?
|
RNA | 1 | 2017 | 568 | 0.110 |
Why?
|
Veterans | 5 | 2016 | 1751 | 0.110 |
Why?
|
Health Behavior | 1 | 2016 | 384 | 0.110 |
Why?
|
Patient Selection | 1 | 2017 | 688 | 0.110 |
Why?
|
United States Department of Defense | 1 | 2013 | 10 | 0.110 |
Why?
|
Heart Rate | 1 | 2015 | 588 | 0.100 |
Why?
|
Cytoskeleton | 1 | 2014 | 178 | 0.100 |
Why?
|
Gene Expression Regulation | 3 | 2014 | 2534 | 0.100 |
Why?
|
Genetic Association Studies | 1 | 2016 | 775 | 0.100 |
Why?
|
Sex Factors | 1 | 2016 | 1267 | 0.100 |
Why?
|
Apoptosis | 2 | 2014 | 1790 | 0.100 |
Why?
|
Sirolimus | 1 | 2014 | 221 | 0.100 |
Why?
|
Medical Oncology | 1 | 2014 | 215 | 0.100 |
Why?
|
Biopolymers | 1 | 2012 | 20 | 0.100 |
Why?
|
Retinal Photoreceptor Cell Outer Segment | 1 | 2011 | 7 | 0.100 |
Why?
|
Transcription Factors | 1 | 2002 | 2607 | 0.100 |
Why?
|
Carbohydrate Metabolism, Inborn Errors | 1 | 2012 | 36 | 0.100 |
Why?
|
Genes, Suppressor | 1 | 2011 | 10 | 0.100 |
Why?
|
MAP Kinase Kinase Kinase 1 | 1 | 2011 | 13 | 0.100 |
Why?
|
Mice | 10 | 2014 | 17734 | 0.100 |
Why?
|
Dark Adaptation | 1 | 2011 | 38 | 0.100 |
Why?
|
Contrast Sensitivity | 1 | 2011 | 59 | 0.100 |
Why?
|
Immunoglobulin Light Chains | 1 | 2011 | 26 | 0.100 |
Why?
|
Visual Field Tests | 1 | 2011 | 48 | 0.100 |
Why?
|
Amyloidogenic Proteins | 1 | 2011 | 6 | 0.090 |
Why?
|
Adult | 4 | 2016 | 29376 | 0.090 |
Why?
|
Biological Assay | 1 | 2012 | 100 | 0.090 |
Why?
|
Mice, Transgenic | 4 | 2014 | 2413 | 0.090 |
Why?
|
Neurotoxins | 1 | 2011 | 56 | 0.090 |
Why?
|
Rats | 3 | 2013 | 3690 | 0.090 |
Why?
|
Osteitis Deformans | 1 | 2011 | 7 | 0.090 |
Why?
|
Mutant Proteins | 1 | 2011 | 112 | 0.090 |
Why?
|
Myositis, Inclusion Body | 1 | 2011 | 8 | 0.090 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 130 | 0.090 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 143 | 0.090 |
Why?
|
Oligopeptides | 1 | 2011 | 117 | 0.090 |
Why?
|
Proteostasis Deficiencies | 1 | 2010 | 5 | 0.090 |
Why?
|
Frontotemporal Dementia | 1 | 2011 | 43 | 0.090 |
Why?
|
Genes, Lethal | 2 | 2013 | 76 | 0.090 |
Why?
|
Patient Satisfaction | 1 | 2014 | 476 | 0.090 |
Why?
|
Exercise | 1 | 2016 | 820 | 0.090 |
Why?
|
Young Adult | 2 | 2016 | 8979 | 0.090 |
Why?
|
Genotype | 2 | 2014 | 2551 | 0.090 |
Why?
|
Blood Pressure | 1 | 2015 | 1322 | 0.090 |
Why?
|
Adenosine Triphosphate | 1 | 2011 | 285 | 0.080 |
Why?
|
Hypersensitivity | 1 | 2012 | 183 | 0.080 |
Why?
|
Alzheimer Vaccines | 1 | 2009 | 1 | 0.080 |
Why?
|
Cerebral Cortex | 1 | 2012 | 455 | 0.080 |
Why?
|
Repetitive Sequences, Amino Acid | 2 | 2006 | 19 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 1 | 2017 | 2087 | 0.080 |
Why?
|
Aged, 80 and over | 6 | 2016 | 6467 | 0.080 |
Why?
|
Gene Knockdown Techniques | 3 | 2016 | 354 | 0.080 |
Why?
|
In Situ Hybridization | 2 | 2006 | 470 | 0.080 |
Why?
|
Healthcare Disparities | 1 | 2013 | 430 | 0.080 |
Why?
|
Diagnosis, Differential | 1 | 2014 | 1887 | 0.080 |
Why?
|
Immunization | 1 | 2010 | 307 | 0.080 |
Why?
|
Microtubules | 1 | 2008 | 197 | 0.070 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 816 | 0.070 |
Why?
|
Bone Morphogenetic Proteins | 1 | 2008 | 127 | 0.070 |
Why?
|
Huntingtin Protein | 2 | 2004 | 63 | 0.070 |
Why?
|
Nerve Tissue Proteins | 2 | 2004 | 1115 | 0.070 |
Why?
|
Brain Injuries | 1 | 2013 | 763 | 0.070 |
Why?
|
Visual Acuity | 1 | 2011 | 814 | 0.070 |
Why?
|
Nuclear Proteins | 2 | 2004 | 1272 | 0.070 |
Why?
|
Hippocampus | 1 | 2012 | 831 | 0.070 |
Why?
|
Cell Cycle Proteins | 1 | 2011 | 645 | 0.070 |
Why?
|
Lung Diseases | 1 | 2010 | 383 | 0.070 |
Why?
|
Protein Structure, Quaternary | 1 | 2006 | 98 | 0.070 |
Why?
|
Computational Biology | 1 | 2011 | 818 | 0.070 |
Why?
|
Cell Count | 1 | 2007 | 252 | 0.070 |
Why?
|
Blotting, Northern | 1 | 2006 | 259 | 0.070 |
Why?
|
Exons | 2 | 2008 | 796 | 0.060 |
Why?
|
Insulin | 1 | 2010 | 1207 | 0.060 |
Why?
|
Substance-Related Disorders | 1 | 2010 | 459 | 0.060 |
Why?
|
Apoptotic Protease-Activating Factor 1 | 1 | 2004 | 11 | 0.060 |
Why?
|
Trinucleotide Repeats | 1 | 2005 | 110 | 0.060 |
Why?
|
Biomarkers | 1 | 2014 | 2976 | 0.060 |
Why?
|
Vaccines | 1 | 2010 | 369 | 0.060 |
Why?
|
Caspase 3 | 1 | 2004 | 134 | 0.060 |
Why?
|
Microscopy, Electron | 1 | 2004 | 395 | 0.060 |
Why?
|
Blotting, Western | 1 | 2006 | 1109 | 0.060 |
Why?
|
Mice, Mutant Strains | 1 | 2004 | 384 | 0.060 |
Why?
|
Caspases | 1 | 2004 | 162 | 0.060 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2011 | 822 | 0.050 |
Why?
|
Dementia | 1 | 2008 | 450 | 0.050 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2006 | 1015 | 0.050 |
Why?
|
Gene Expression | 1 | 2008 | 1569 | 0.050 |
Why?
|
Carrier Proteins | 1 | 2008 | 1024 | 0.050 |
Why?
|
Glycogen Synthase Kinases | 1 | 2002 | 6 | 0.050 |
Why?
|
Armadillo Domain Proteins | 1 | 2002 | 9 | 0.050 |
Why?
|
Primidone | 1 | 2022 | 9 | 0.050 |
Why?
|
High Mobility Group Proteins | 1 | 2002 | 32 | 0.050 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2002 | 45 | 0.050 |
Why?
|
Recombinant Proteins | 3 | 2012 | 1392 | 0.050 |
Why?
|
Feedback | 1 | 2023 | 162 | 0.050 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2002 | 118 | 0.050 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2011 | 1241 | 0.050 |
Why?
|
Propranolol | 1 | 2022 | 129 | 0.050 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2001 | 75 | 0.050 |
Why?
|
beta Catenin | 1 | 2002 | 206 | 0.040 |
Why?
|
Cytoskeletal Proteins | 1 | 2002 | 268 | 0.040 |
Why?
|
Glutamine | 1 | 2001 | 210 | 0.040 |
Why?
|
Repressor Proteins | 2 | 2002 | 821 | 0.040 |
Why?
|
Protein Conformation | 2 | 2012 | 833 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2008 | 2613 | 0.040 |
Why?
|
Gene Expression Profiling | 1 | 2006 | 1694 | 0.040 |
Why?
|
Saccharomyces cerevisiae Proteins | 1 | 2001 | 276 | 0.040 |
Why?
|
Neuroblastoma | 2 | 2014 | 520 | 0.040 |
Why?
|
Abnormalities, Multiple | 1 | 2005 | 964 | 0.040 |
Why?
|
Enzyme Inhibitors | 1 | 2001 | 579 | 0.040 |
Why?
|
Registries | 2 | 2016 | 1410 | 0.040 |
Why?
|
Adolescent | 1 | 2016 | 19355 | 0.040 |
Why?
|
Health Services Accessibility | 2 | 2014 | 605 | 0.040 |
Why?
|
Microelectrodes | 1 | 2016 | 42 | 0.030 |
Why?
|
Models, Biological | 2 | 2012 | 1459 | 0.030 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2016 | 121 | 0.030 |
Why?
|
Electroretinography | 1 | 2016 | 114 | 0.030 |
Why?
|
North Carolina | 1 | 2016 | 58 | 0.030 |
Why?
|
Signal Transduction | 1 | 2008 | 4533 | 0.030 |
Why?
|
Vision, Ocular | 1 | 2016 | 122 | 0.030 |
Why?
|
Pandemics | 1 | 2023 | 1102 | 0.030 |
Why?
|
Blood Pressure Determination | 1 | 2015 | 103 | 0.030 |
Why?
|
Membrane Potentials | 1 | 2016 | 304 | 0.030 |
Why?
|
SEER Program | 1 | 2016 | 199 | 0.030 |
Why?
|
Clergy | 1 | 2014 | 4 | 0.030 |
Why?
|
Prions | 1 | 2014 | 13 | 0.030 |
Why?
|
Cellular Structures | 1 | 2014 | 2 | 0.030 |
Why?
|
Cardiovascular System | 1 | 2015 | 102 | 0.030 |
Why?
|
Myelin Basic Protein | 1 | 2014 | 69 | 0.030 |
Why?
|
Neurogenesis | 1 | 2016 | 192 | 0.030 |
Why?
|
Glycerolphosphate Dehydrogenase | 1 | 2013 | 4 | 0.030 |
Why?
|
Immunoprecipitation | 1 | 2014 | 199 | 0.030 |
Why?
|
Protein Structure, Tertiary | 2 | 2009 | 755 | 0.030 |
Why?
|
Wings, Animal | 1 | 2013 | 32 | 0.030 |
Why?
|
Cooperative Behavior | 1 | 2014 | 220 | 0.030 |
Why?
|
Cerebrospinal Fluid Pressure | 1 | 2013 | 16 | 0.030 |
Why?
|
Injections, Intraventricular | 1 | 2012 | 64 | 0.030 |
Why?
|
Larva | 1 | 2013 | 248 | 0.030 |
Why?
|
Health Surveys | 1 | 2014 | 244 | 0.030 |
Why?
|
Solutions | 1 | 2012 | 65 | 0.030 |
Why?
|
Hydrophobic and Hydrophilic Interactions | 1 | 2012 | 57 | 0.030 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2014 | 124 | 0.030 |
Why?
|
Hypoadrenocorticism, Familial | 1 | 2012 | 2 | 0.020 |
Why?
|
Pigment Epithelium of Eye | 1 | 2012 | 37 | 0.020 |
Why?
|
Excitatory Postsynaptic Potentials | 1 | 2012 | 131 | 0.020 |
Why?
|
Immunoglobulin lambda-Chains | 1 | 2011 | 11 | 0.020 |
Why?
|
Immunoglobulin Light-chain Amyloidosis | 1 | 2011 | 10 | 0.020 |
Why?
|
Immunoglobulin kappa-Chains | 1 | 2011 | 31 | 0.020 |
Why?
|
Imaging, Three-Dimensional | 1 | 2014 | 371 | 0.020 |
Why?
|
Fluorescence Resonance Energy Transfer | 1 | 2012 | 64 | 0.020 |
Why?
|
Water-Electrolyte Balance | 1 | 2012 | 80 | 0.020 |
Why?
|
Hematoxylin | 1 | 2011 | 8 | 0.020 |
Why?
|
Eosine Yellowish-(YS) | 1 | 2011 | 9 | 0.020 |
Why?
|
Congo Red | 1 | 2011 | 7 | 0.020 |
Why?
|
Birefringence | 1 | 2011 | 11 | 0.020 |
Why?
|
Microscopy, Polarization | 1 | 2011 | 10 | 0.020 |
Why?
|
Keratinocytes | 1 | 2011 | 61 | 0.020 |
Why?
|
Benzothiazoles | 1 | 2011 | 30 | 0.020 |
Why?
|
Neuroimaging | 1 | 2014 | 340 | 0.020 |
Why?
|
Dermis | 1 | 2011 | 24 | 0.020 |
Why?
|
Valosin Containing Protein | 1 | 2011 | 6 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2010 | 4425 | 0.020 |
Why?
|
Patient-Centered Care | 1 | 2014 | 225 | 0.020 |
Why?
|
Epidermis | 1 | 2011 | 60 | 0.020 |
Why?
|
Long-Term Potentiation | 1 | 2012 | 164 | 0.020 |
Why?
|
Ubiquitination | 1 | 2012 | 174 | 0.020 |
Why?
|
Coloring Agents | 1 | 2011 | 79 | 0.020 |
Why?
|
Antibody Specificity | 1 | 2011 | 202 | 0.020 |
Why?
|
DNA Primers | 1 | 2012 | 660 | 0.020 |
Why?
|
Microscopy | 1 | 2011 | 117 | 0.020 |
Why?
|
Injections, Intradermal | 1 | 2010 | 31 | 0.020 |
Why?
|
Chemical Precipitation | 1 | 2010 | 15 | 0.020 |
Why?
|
Thiazoles | 1 | 2011 | 97 | 0.020 |
Why?
|
Injections, Intralesional | 1 | 2010 | 46 | 0.020 |
Why?
|
Staining and Labeling | 1 | 2011 | 187 | 0.020 |
Why?
|
Odds Ratio | 1 | 2014 | 1246 | 0.020 |
Why?
|
Protein Folding | 1 | 2011 | 218 | 0.020 |
Why?
|
Retrospective Studies | 2 | 2022 | 16225 | 0.020 |
Why?
|
Protein Structure, Secondary | 1 | 2010 | 239 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2014 | 1417 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2010 | 152 | 0.020 |
Why?
|
Ubiquitin | 1 | 2011 | 142 | 0.020 |
Why?
|
Caspase 9 | 1 | 2010 | 75 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2013 | 1231 | 0.020 |
Why?
|
Adenosine Triphosphatases | 1 | 2011 | 208 | 0.020 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2012 | 508 | 0.020 |
Why?
|
Administration, Inhalation | 1 | 2010 | 180 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2012 | 1018 | 0.020 |
Why?
|
Qualitative Research | 1 | 2013 | 545 | 0.020 |
Why?
|
Endopeptidase K | 1 | 2009 | 4 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2016 | 2871 | 0.020 |
Why?
|
Cell Membrane | 1 | 2011 | 460 | 0.020 |
Why?
|
Algorithms | 1 | 2016 | 1612 | 0.020 |
Why?
|
Substantia Nigra | 1 | 2009 | 34 | 0.020 |
Why?
|
Diabetes Complications | 1 | 2010 | 196 | 0.020 |
Why?
|
Chromosomes, Artificial, Bacterial | 1 | 2009 | 93 | 0.020 |
Why?
|
Corpus Striatum | 1 | 2009 | 91 | 0.020 |
Why?
|
Incidence | 1 | 2016 | 3086 | 0.020 |
Why?
|
Emergency Service, Hospital | 1 | 2016 | 1089 | 0.020 |
Why?
|
Disease Progression | 1 | 2014 | 2038 | 0.020 |
Why?
|
Introns | 1 | 2008 | 300 | 0.020 |
Why?
|
Macrophages | 1 | 2011 | 618 | 0.020 |
Why?
|
Puromycin | 1 | 2006 | 11 | 0.020 |
Why?
|
Survival Rate | 1 | 2012 | 2020 | 0.020 |
Why?
|
Transfection | 1 | 2009 | 1069 | 0.020 |
Why?
|
Biopsy | 1 | 2010 | 1237 | 0.020 |
Why?
|
Fibroblasts | 1 | 2011 | 890 | 0.020 |
Why?
|
Genetic Markers | 1 | 2008 | 606 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2008 | 788 | 0.020 |
Why?
|
Alleles | 1 | 2011 | 1614 | 0.020 |
Why?
|
Blood Glucose | 1 | 2010 | 1129 | 0.020 |
Why?
|
Chronic Disease | 1 | 2010 | 1182 | 0.020 |
Why?
|
Subcellular Fractions | 1 | 2005 | 98 | 0.020 |
Why?
|
Structure-Activity Relationship | 1 | 2006 | 568 | 0.020 |
Why?
|
Cross-Sectional Studies | 1 | 2014 | 3426 | 0.020 |
Why?
|
Cell Line | 1 | 2010 | 2770 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2009 | 940 | 0.020 |
Why?
|
COS Cells | 1 | 2005 | 276 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2008 | 1341 | 0.010 |
Why?
|
Models, Animal | 1 | 2006 | 466 | 0.010 |
Why?
|
Genes, Recessive | 1 | 2005 | 179 | 0.010 |
Why?
|
Kinetics | 1 | 2006 | 1321 | 0.010 |
Why?
|
Linkage Disequilibrium | 1 | 2005 | 309 | 0.010 |
Why?
|
DNA, Complementary | 1 | 2005 | 464 | 0.010 |
Why?
|
Quality of Life | 1 | 2014 | 1951 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2005 | 657 | 0.010 |
Why?
|
Fetal Development | 1 | 2005 | 131 | 0.010 |
Why?
|
Sin3 Histone Deacetylase and Corepressor Complex | 1 | 2001 | 5 | 0.010 |
Why?
|
PC12 Cells | 1 | 2001 | 26 | 0.010 |
Why?
|
CREB-Binding Protein | 1 | 2001 | 63 | 0.010 |
Why?
|
Acetyltransferases | 1 | 2001 | 90 | 0.010 |
Why?
|
E1A-Associated p300 Protein | 1 | 2001 | 52 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2008 | 3267 | 0.010 |
Why?
|
Acetylation | 1 | 2001 | 175 | 0.010 |
Why?
|
Glutathione Transferase | 1 | 2001 | 153 | 0.010 |
Why?
|
Histone Deacetylases | 1 | 2001 | 114 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2005 | 2699 | 0.010 |
Why?
|
Histone Acetyltransferases | 1 | 2001 | 313 | 0.010 |
Why?
|
Base Sequence | 1 | 2005 | 3093 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2005 | 3873 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2005 | 2824 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2014 | 12279 | 0.010 |
Why?
|
Histones | 1 | 2001 | 534 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2008 | 3134 | 0.010 |
Why?
|